UTHR - United Therapeutics ...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $163.21 | Open | |
| Volume | Market Cap | 7.403B | |
| Yield | Last Dividend |
| United axes PAH program Trevyent, once b... | 03/03/21 |
| About three years after acquiring SteadyMed and its experimental pulmonary arterial hypertension drug Trevyent, United Therapeutics has decided to kic... | |
| United Therapeutics Pulls Plug On Trevye... | 03/03/21 |
| Based on the FDA???s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent. Trevyent... | |
| United Therapeutics Pulls Plug On Trevye... | 03/03/21 |
| Based on the FDA???s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the ??? | |
| Insights on the Systemic Scleroderma Tre... | 03/01/21 |
| DUBLIN, March 1, 2021 /PRNewswire/ -- The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regi... | |
| The Daily Biotech Pulse: Aridis To Study... | 02/23/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acc... | |
| United Therapeutics (UTHR) to Release Qu... | 02/18/21 |
| United Therapeutics (NASDAQ:UTHR) is set to announce its earnings results before the market opens on Wednesday, February 24th. Analysts expect the com... | |
| The Daily Biotech Pulse: Lily-Rigel Lice... | 02/18/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Adv... | |
| Alembic Global Holding SA gets USFDA nod... | 02/12/21 |
| Drug firm Alembic Pharmaceuticals on Friday said its arm, Alembic Global Holding SA, has received approval from the US health regulator for its generi... | |
| Hydrosurgery Systems Market Report Exami... | 02/05/21 |
| Hydrosurgery systems are seamlessly scaling up as a highly preferred treatment protocol over conventional wound debridement methods. In particular, ha... | |
| Pediatric Neuroblastoma Treatment Market... | 02/05/21 |
| Preference as a precautionary healthcare procedure for immunocompromised children continue to bolster the growth of pediatric neuroblastoma treatment ... | |
| The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... | |
| Pediatric Neuroblastoma Treatment Market... | 11/25/20 |
| The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the... | |
| The Daily Biotech Pulse: Setback For Alk... | 11/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Ali... | |
| The Daily Biotech Pulse: Bluebird Bio Pl... | 11/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbo... | |
| The Daily Biotech Pulse: Aurinia Pulls T... | 11/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-... | |
| Global Exosome Therapeutic Market Growth... | 11/02/20 |
| Data Bridge Market Research has recently added a concise research on the Exosome Therapeutic Market to depict valuable insights related to significant... | |
| United Therapeutics EPS beats by $0.54, ... | 10/28/20 |
| United Therapeutics (NASDAQ:UTHR): Q3 Non-GAAP EPS of $3.88 beats by $0.54; GAAP EPS of $3.84 beats by $1.16. Revenue of $380.1M (-5.3% Y/Y) beats by ... | |
| United Therapeutics Co. (NASDAQ:UTHR) Ex... | 10/23/20 |
| Equities analysts expect that United Therapeutics Co. (NASDAQ:UTHR) will report $2.41 earnings per share (EPS) for the current quarter, Zacks reports.... | |
| United Therapeutics (UTHR) to Release Ea... | 10/22/20 |
| United Therapeutics (NASDAQ:UTHR) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, October 28th. Analys... | |
| Pulmonary Arterial Hypertension Market I... | 10/20/20 |
| Global Pulmonary Arterial Hypertension Market is expected to rise gradually to an estimated value of USD 9.13 billion by 2026, registering a CAGR of 5... | |
| Global Exosome Therapeutic Market Outloo... | 10/19/20 |
| A DBMR team makes use of simple language and easy to understand statistical images to provide thorough information and in-depth data on the industry a... | |
| Patient Controlled Injectors Market New ... | 10/16/20 |
| This research report will give you deep insights about the Patient Controlled Injectors Market and it will also help you in strategic decision making.... | |
| Exosome therapeutic Market Comprehensive... | 10/14/20 |
| A most recent review on Exosome therapeutic Market is led covering different associations of the business from various topographies to think of 100+ p... | |
| Neuroblastoma Drug Market Demand, Growth... | 10/13/20 |
| The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market driv... | |
| Global exosome therapeutic market Surpri... | 10/12/20 |
| Data Bridge Market Research has recently added a concise research on the Exosome Therapeutic Market to depict valuable insights related to significant... | |
| Global exosome therapeutic market Is Pro... | 10/07/20 |
| Exosome Therapeutic Market research report has been prepared with a nice combination of industry insight, smart solutions, practical solutions and new... | |
| CollPlant and United Therapeutics Announ... | 09/21/20 |
| REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporati... | |
| United Therapeutics Corporation Appoints... | 09/11/20 |
| SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the... | |
| United Therapeutics Scores FDA Nod For N... | 08/17/20 |
| United Therapeutics (UTHR) has announced that the U.S. The post United Therapeutics Scores FDA Nod For New Tyvaso Review appeared first on Smarter Ana... | |
| United Therapeutics Announces U.S. FDA F... | 08/17/20 |
| /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review th... | |
| Strong Buy rating | 02/22/21 |
| Credit Suisse maintains Outperform rating and raises Price Target from $169.00 to $196.00 | |
| Strong Buy rating | 02/16/21 |
| Oppenheimer maintains Outperform rating and raises Price Target from $200.00 to $275.00 | |
| Buy rating | 02/01/21 |
| HC Wainwright & Co. upgrades from Neutral to Buy rating and raises Price Target from $125.00 to $195.00 | |
| Date | 2021-02-24 (BMO) | Est. (EPS/Rev.) | $3.14/ 361.07M |
| Actual (EPS/Rev.) | $3.31/ $384.90 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Analyst Rating Investments | BigMoveTrader | 67.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
